That’s the sort of drug we need…
However, because fenofibrate does not readily cross the blood-brain barrier, the scientists had to administer very high doses of the drug. That approach would be risky in people, says Maekawa, since fenofibrate can sometimes seriously damage muscle tissue. To avoid that potential side effect, drug developers may have to refine the chemistry of fenofibrate or discover new agents that activate PPARα. “To test the therapeutic strategy in people, we need more drugs that penetrate the brain for clinical trials,” Maekawa says.
They’ll have to come up with some way to deliver it to the brain, or a different version of it - both of which probably aren’t impossible, but probably will take awhile.